<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871152</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-TOX-2020-67</org_study_id>
    <nct_id>NCT04871152</nct_id>
  </id_info>
  <brief_title>Trip-Tox, Effectiveness of Triptans Before and After Onabotulinumtoxin A Treatment in Chronic Migraine</brief_title>
  <official_title>Trip-tox Study. Analysis of the Efficacy and Satisfaction of Symptomatic Treatment With Triptans in Patients With Chronic Migraine Undergoing onabotulinumtoxinA Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, longitudinal, prospective, prospective, comparative study of the effectiveness&#xD;
      of triptans before and after onabotulintoxin A initiation in a single group of chronic&#xD;
      migraine patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis In patients with chronic migraine the efficacy of triptans, previously taken by&#xD;
      the patient for the migraine attack, is better and more satisfactory after starting treatment&#xD;
      with onabotulinumtoxinA.&#xD;
&#xD;
      Objectives To analyze the efficacy and satisfaction of the triptan usually taken by the&#xD;
      patient with chronic migraine before starting preventive treatment with onabotulinumtoxinA,&#xD;
      at 4 months, after two sessions of Botox, and at 7 months of treatment, after three sessions&#xD;
      of Botox.&#xD;
&#xD;
      Sample size n=100 patients with chronic migraine in whom treatment with onabotulinumtoxinA is&#xD;
      indicated. The indication for Botox treatment will be performed as usual and the patient will&#xD;
      take his usual triptan if he has a migraine attack, so there is no therapeutic modification&#xD;
      in this study that could involve any bioethical issue.&#xD;
&#xD;
      All patients signed the informed consent and the study was approved by the Comitè d'Ètica de&#xD;
      la Investigació amb Medicaments (CEIm) de l'Hospital de la Santa Creu i Sant Pau.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change efficacy (Pain free at two hours )</measure>
    <time_frame>From baseline to 4 months</time_frame>
    <description>Percentage of patients who are completely free of pain after two hours of ingestion of their usual triptan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change efficacy (Pain free at two hours )</measure>
    <time_frame>From baseline to 7 months</time_frame>
    <description>Percentage of patients who are completely free of pain after two hours of ingestion of their usual triptan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction (Likert scale 1-5)</measure>
    <time_frame>From baseline to 4 months</time_frame>
    <description>Satisfaction of treatment with triptans before and after treatment with OnabotulinumtoxinA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction (Likert scale 1-5)</measure>
    <time_frame>From baseline to 7 months</time_frame>
    <description>Satisfaction of treatment with triptans before and after treatment with OnabotulinumtoxinA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain free at one hour</measure>
    <time_frame>4 and 7 months</time_frame>
    <description>Percentage of patients who are completely free of pain after one hour of ingestion of their usual triptan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained pain-free</measure>
    <time_frame>4 and 7 months</time_frame>
    <description>Percentage of patients who achieve pain-free at two hours and do not require rescue medication within 24-48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache relapse</measure>
    <time_frame>4 and 7 months</time_frame>
    <description>Percentage of patients experiencing recurrence of pain within 48 h on triptans with long half-life or 24 h on triptans with short half-life.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Patients with chronic migraine</arm_group_label>
    <description>In the same group of patients, the response to triptans will be analyzed at 3 different times with respect to the start of treatment with onabotulinumtoxinA: before treatment, after 4 months and after 7 months of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.</description>
    <arm_group_label>Patients with chronic migraine</arm_group_label>
    <other_name>Triptans</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet criteria for chronic migraine and have failed 2 or more oral preventive&#xD;
        treatments (including topiramate) or have a contraindication to taking topiramate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICHD-3 criteria for chronic migraine (code 1.3). See Table 3.&#xD;
&#xD;
          -  Older than 18 years and younger than 65 years.&#xD;
&#xD;
          -  Migraine started in their lifetime before the age of 50 years.&#xD;
&#xD;
          -  Migraine of more than one year of evolution since diagnosis.&#xD;
&#xD;
          -  Normal cranial CT/MRI study.&#xD;
&#xD;
          -  Indication for treatment with Botox&#xD;
&#xD;
          -  Taking triptans as a rescue treatment for migraine attacks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Migraine of less than one year of evolution since diagnosis.&#xD;
&#xD;
          -  Pathologies that contraindicate the use of OnabotulinumtoxinA (myasthenia gravis,&#xD;
             myopathies).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Belvís, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Belvís, PhD</last_name>
    <phone>+34 93 291 90 00</phone>
    <email>rbelvis@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Headache and Neuralgia Unit. Neurology Department. Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Belvís, PhD</last_name>
      <phone>+34 93 291 90 00</phone>
      <email>rbelvis@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

